Apunts Medicina de l'Esport (English Edition) Apunts Medicina de l'Esport (English Edition)
Apunts Med Esport. 2014;49:31-6 - Vol. 49 Num.182

The efficacy and safety of oral mucopolysaccharide, type I collagen and vitamin C treatment in tendinopathy patients

Andreu Arquer a, Miquel García b, José Antonio Laucirica c, Marta Rius d, Marian Blàvia e, Jaume Fontserè f, Carlos Hernández g, Jordi Boluda h, Tomislav Kranjcec i, Ana de la Torre j, Gilberto Díaz k, Karin Freitag l, José M. Villalón m, Jaime Baselga n, Pedro Hernández n, José Gonzalez o, Guillermo Rodríguez o, Horacio Rodríguez p, Juan María Alarcón p, Carlos T. Simorte q, Isaac Vicente r, Montserrat Cabanas r, Pablo Ramírez r, Daniel Martínez Puig r

a Centre d’Alt Rendiment (CAR-GIRSANE), Sant Cugat del Vallès, Barcelona, España
b Clínica Teknon, Barcelona, España
c Artro Esport, Barcelona, España
d Mútua Catalana de Fútbol, Barcelona, España
e Clínica Diagonal, Esplugues de Llobregat, Barcelona, España
f Traumasalut, Sabadell, Barcelona, España
g Unitat de Medicina de l’Esport, Xarxa Sanitària i Social de Santa Tecla, Tarragona, España
h Lenox Corachan, Barcelona, España
i Activa Mútua, Clínica Diagonal y Centros, Barcelona, España
j Clínica CEMTRO, Madrid, España
k Clínica Asepeyo, Madrid, España
l Centro Integral del Aparato Locomotor, Madrid, España
m Hospital Universitario Montepríncipe, Madrid, España
n Hospital Ruber Internacional, Madrid, España
o Clínica DEYRE, Madrid, España
p Clínica Nuestra Señora de América, Madrid, España
q Hospital de Madrid, Madrid, España
r Bioibérica S.A., Palafolls, Barcelona, España

Keywords

Tendinopathy. Clinical trial. Diet supplement.

Abstract

Introduction and objectives

Tendinopathy, which is accompanied by structural changes to the tendon, is a common sporting injury. The aim of this study was to evaluate the efficacy and safety of a nutritional supplement containing mucopolysaccharides, type I collagen and vitamin C (TendoactiveTM) on the clinical and structural evolution of tendinopathies of the Achilles tendon, patellar tendon and lateral epicondyle tendon in the elbow.

Materials and methods

A multicenter, open-label, non-comparative, prospective, exploratory phase iv study was performed. A total of 98 tendinopathy patients (32 Achilles, 32 patellar and 34 lateral epicondylar), who received a daily dose of 435 mg mucopolysaccharides, 75 mg type i collagen and 60 mg vitamin C (equivalent to three capsules of TendoactiveTM per day) for 90 consecutive days, were included. Every month, pain at rest and when active was assessed using a visual analogue scale (VAS), joint function was assessed using the VISA-A, VISA-P and PRTEE questionnaires, and the tendon affected was characterized by ultrasound.

Results

A significant reduction in pain both at rest and when active was observed between the first control visit (day 30) and the end of the study (day 90) for all three types of tendinopathy. Thus, a 38% improvement in VISA-A, 46% in VISA-P and 77% in PRTEE was observed on day 90 (P < .001). Similarly, a 12% decrease in the thickness of the Achilles tendon, a 10% decrease in the patellar tendon and a 20% decrease in the lateral epicondyle tendon was observed (P < .05).

Conclusions

The results of this study show that the administration of TendoactiveTM is safe and effective for improving the clinical symptoms and structural evolution of tendinopathies of the Achilles, patella and lateral epicondyle tendons.